Vorinostat in Combination With Vinorelbine in Patients With Advanced Cancer
A Phase I Clinical Trial of Vorinostat in Combination With Vinorelbine in Patients With Advanced Cancer.
Sponsor: Institut Claudius Regaud
Terminated
This trial was terminated. No reason was provided.
A PHASE1 clinical study on Malignant Solid Tumour, this trial is terminated or withdrawn. The trial is conducted by Institut Claudius Regaud and has accumulated 6 data snapshots since 2009. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Jun 2022 — Jul 2024 [monthly]
Terminated PHASE1
-
Jan 2021 — Jun 2022 [monthly]
Terminated PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE1
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE1
First recorded
Jan 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Institut Claudius Regaud
- Merck Sharp & Dohme LLC
For direct contact, visit the study record on ClinicalTrials.gov .